MedTrace Logo

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

NCT06439056 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-23

No results posted yet for this study

Summary

The purpose with the study is to assess pharmacokinetics of NEX-22A in patients with type 2 diabetes.

Conditions

Interventions

DRUG

NEX-22A, a prolonged release formulation of liraglutide

NEX-22A, a prolonged release formulation of liraglutide

Sponsors & Collaborators

  • Profil Institut für Stoffwechselforschung GmbH

    collaborator INDUSTRY

  • Nanexa AB

    lead INDUSTRY

Principal Investigators

  • Grit Andersen, MD · Profil Institut für Stoffwechselforschung GmbH Hellersbergstr. 9 D-41460 Neuss

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-27
Primary Completion
2025-07-18
Completion
2025-07-18

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06439056 on ClinicalTrials.gov